Tech-enabled drug discovery company Insilico Medicine secured $110 million in an oversubscribed Series E funding round.
A large equity fund of Value Partners Group, an asset management firm in Asia, and new and existing investors participated in the round.
WHAT IT DOES
Massachusetts-based Insilico's proprietary generative AI platform, Pharma.AI, utilizes biology, clinical medicine, scientific...
Drug discovery startup Insilico Medicine and Italian pharmaceutical company Menarini Group announced their second licensing agreement, which targets unmet needs in oncology with a novel AI-discovered preclinical asset.
The agreement grants Stemline Therapeutics, a subsidiary of Menarini, global rights to develop and commercialize a selective small molecule inhibitor with broad antitumor activity...
Aledade, which works with primary care providers to build tech-enabled accountable care organizations, raised $123 million in a Series E funding round led by OMERS Growth Equity.
Other participants in the round include Fidelity Management and Research Company and other current investors. The raise brings the startup's valuation to $3.1 billion, according to reporting by Insider.
Aledade said it...
Drug-discovery startup Insilico Medicine has scored a whopping $225 million in a Series C funding round led by Warburg Pincus.
This comes roughly two years after the New York and Hong Kong-based startup raised $37 million in Series B funding. The company now boasts of more than $310 million in funding.
Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures,...
_16e091.jpg)
